These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 23650463)

  • 1. Current and emerging therapies for the treatment of multiple sclerosis: focus on cladribine.
    Schreiner TL; Miravalle A
    J Cent Nerv Syst Dis; 2012; 4():1-14. PubMed ID: 23650463
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis.
    Filippini G; Del Giovane C; Vacchi L; D'Amico R; Di Pietrantonj C; Beecher D; Salanti G
    Cochrane Database Syst Rev; 2013 Jun; 2013(6):CD008933. PubMed ID: 23744561
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis.
    Filippini G; Del Giovane C; Clerico M; Beiki O; Mattoscio M; Piazza F; Fredrikson S; Tramacere I; Scalfari A; Salanti G
    Cochrane Database Syst Rev; 2017 Apr; 4(4):CD012200. PubMed ID: 28440858
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New and Emerging Disease-Modifying Therapies for Relapsing-Remitting Multiple Sclerosis: What is New and What is to Come.
    Nicholas J; Morgan-Followell B; Pitt D; Racke MK; Boster A
    J Cent Nerv Syst Dis; 2012; 4():81-103. PubMed ID: 23650470
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current and future therapies for multiple sclerosis.
    Minagar A
    Scientifica (Cairo); 2013; 2013():249101. PubMed ID: 24278770
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potential short-term use of oral cladribine in treatment of relapsing-remitting multiple sclerosis.
    Murphy JA; Harris JA; Crannage AJ
    Neuropsychiatr Dis Treat; 2010 Oct; 6():619-25. PubMed ID: 20957121
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative efficacy and acceptability of disease-modifying therapies in patients with relapsing-remitting multiple sclerosis: a systematic review and network meta-analysis.
    Li H; Hu F; Zhang Y; Li K
    J Neurol; 2020 Dec; 267(12):3489-3498. PubMed ID: 31129710
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multiple sclerosis: pathogenesis and treatment.
    Loma I; Heyman R
    Curr Neuropharmacol; 2011 Sep; 9(3):409-16. PubMed ID: 22379455
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An update on new and emerging therapies for relapsing-remitting multiple sclerosis.
    Weinstock-Guttman B
    Am J Manag Care; 2013 Nov; 19(17 Suppl):s343-54. PubMed ID: 24494635
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative effectiveness and cost-effectiveness of natalizumab and fingolimod in rapidly evolving severe relapsing-remitting multiple sclerosis in the United Kingdom.
    Spelman T; Herring WL; Acosta C; Hyde R; Jokubaitis VG; Pucci E; Lugaresi A; Laureys G; Havrdova EK; Horakova D; Izquierdo G; Eichau S; Ozakbas S; Alroughani R; Kalincik T; Duquette P; Girard M; Petersen T; Patti F; Csepany T; Granella F; Grand'Maison F; Ferraro D; Karabudak R; Jose Sa M; Trojano M; van Pesch V; Van Wijmeersch B; Cartechini E; McCombe P; Gerlach O; Spitaleri D; Rozsa C; Hodgkinson S; Bergamaschi R; Gouider R; Soysal A; Castillo-Triviño ; Prevost J; Garber J; de Gans K; Ampapa R; Simo M; Sanchez-Menoyo JL; Iuliano G; Sas A; van der Walt A; John N; Gray O; Hughes S; De Luca G; Onofrj M; Buzzard K; Skibina O; Terzi M; Slee M; Solaro C; Oreja-Guevara ; Ramo-Tello C; Fragoso Y; Shaygannejad V; Moore F; Rajda C; Aguera Morales E; Butzkueven H
    J Med Econ; 2024; 27(1):109-125. PubMed ID: 38085684
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Teriflunomide for multiple sclerosis.
    He D; Zhang C; Zhao X; Zhang Y; Dai Q; Li Y; Chu L
    Cochrane Database Syst Rev; 2016 Mar; 3(3):CD009882. PubMed ID: 27003123
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Laquinimod for multiple sclerosis.
    He D; Han K; Gao X; Dong S; Chu L; Feng Z; Wu S
    Cochrane Database Syst Rev; 2013 Aug; (8):CD010475. PubMed ID: 23922214
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risks vs benefits of glatiramer acetate: a changing perspective as new therapies emerge for multiple sclerosis.
    Johnson KP
    Ther Clin Risk Manag; 2010 Apr; 6():153-72. PubMed ID: 20421914
    [TBL] [Abstract][Full Text] [Related]  

  • 14. What is new in the treatment of multiple sclerosis?
    Weinstock-Guttman B; Jacobs LD
    Drugs; 2000 Mar; 59(3):401-10. PubMed ID: 10776827
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drugs for multiple sclerosis.
    Med Lett Drugs Ther; 2021 Mar; 63(1620):42-48. PubMed ID: 33976089
    [No Abstract]   [Full Text] [Related]  

  • 16. Cladribine (Mavenclad) for multiple sclerosis.
    Med Lett Drugs Ther; 2019 Jul; 61(1577):118-120. PubMed ID: 31381552
    [No Abstract]   [Full Text] [Related]  

  • 17. Teriflunomide for multiple sclerosis.
    He D; Xu Z; Dong S; Zhang H; Zhou H; Wang L; Zhang S
    Cochrane Database Syst Rev; 2012 Dec; 12():CD009882. PubMed ID: 23235682
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparing the cost-effectiveness of disease-modifying drugs for the first-line treatment of relapsing-remitting multiple sclerosis.
    Goldberg LD; Edwards NC; Fincher C; Doan QV; Al-Sabbagh A; Meletiche DM
    J Manag Care Pharm; 2009 Sep; 15(7):543-55. PubMed ID: 19739877
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.